相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC
Chenhe Yi et al.
HEPATOLOGY (2021)
Different Mechanisms of Action of Regorafenib and Lenvatinib on Toll-Like Receptor-Signaling Pathways in Human Hepatoma Cell Lines
Reina Sasaki et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC
Jaejun Lee et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models
Masahiro Matsuki et al.
CANCER MEDICINE (2018)
Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular Carcinoma
Masatoshi Kudo
LIVER CANCER (2018)
Modulating ROS to overcome multidrug resistance in cancer
Qingbin Cui et al.
DRUG RESISTANCE UPDATES (2018)
miR-139-5p Modulates Radiotherapy Resistance in Breast Cancer by Repressing Multiple Gene Networks of DNA Repair and ROS Defense
Marina Pajic et al.
CANCER RESEARCH (2018)
Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses
Toshiyuki Tamai et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
FGF19 Protects Hepatocellular Carcinoma Cells against Endoplasmic Reticulum Stress via Activation of FGFR4-GSK3β-Nrf2 Signaling
Yong Teng et al.
CANCER RESEARCH (2017)
YAP Suppresses Lung Squamous Cell Carcinoma Progression via Deregulation of the DNp63-GPX2 Axis and ROS Accumulation
Hsinyi Huang et al.
CANCER RESEARCH (2017)
Activation of apoptosis signalling pathways by reactive oxygen species
Maureen Redza-Dutordoir et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2016)
Clinicopathological and prognostic significance of GPX2 protein expression in esophageal squamous cell carcinoma
Zhijin Lei et al.
BMC CANCER (2016)
Lenvatinib: Role in thyroid cancer and other solid tumors
Maria E. Cabanillas et al.
CANCER TREATMENT REVIEWS (2016)
Genotype-Phenotype Correlation of CTNNB1 Mutations Reveals Different β-Catenin Activity Associated With Liver Tumor Progression
Sandra Rebouissou et al.
HEPATOLOGY (2016)
1,25-Dihydroxyvitamin D3 alleviates salivary adenoid cystic carcinoma progression by suppressing GPX1 expression through the NF-κB pathway
Zhiquan Huang et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib
Aline Houessinon et al.
MOLECULAR CANCER (2016)
Erlotinib induces the human non-small-cell lung cancer cells apoptosis via activating ROS-dependent JNK pathways
Fenglian Shan et al.
CANCER MEDICINE (2016)
Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
Calin Cainap et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
GPx2 Suppression of H2O2 Stress Links the Formation of Differentiated Tumor Mass to Metastatic Capacity in Colorectal Cancer
Benjamin L. Emmink et al.
CANCER RESEARCH (2014)
GPX2 overexpression is involved in cell proliferation and prognosis of castration-resistant prostate cancer
Taku Naiki et al.
CARCINOGENESIS (2014)
Regulation of Ferroptotic Cancer Cell Death by GPX4
Wan Seok Yang et al.
CELL (2014)
Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models
Osamu Tohyama et al.
JOURNAL OF THYROID RESEARCH (2014)
Glutathione peroxidases
Regina Brigelius-Flohe et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2013)
Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models
Kiyoshi Okamoto et al.
CANCER LETTERS (2013)
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
Philip J. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
Ann-Lii Cheng et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Epigenetic change in kidney tumor: downregulation of histone acetyltransferase MYST1 in human renal cell carcinoma
Yong Wang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2013)
Expression of glutathione peroxidase 2 is associated with not only early hepatocarcinogenesis but also late stage metastasis
Shugo Suzuki et al.
TOXICOLOGY (2013)
Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma
Seiki Miura et al.
BMC CANCER (2012)
Sorafenib-Induced Hepatocellular Carcinoma Cell Death Depends on Reactive Oxygen Species Production In Vitro and In Vivo
Romain Coriat et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Activation of the glutathione peroxidase 2 (GPx2) promoter by β-catenin
Anna Kipp et al.
BIOLOGICAL CHEMISTRY (2007)
分享论文
